Company Filing History:
Years Active: 2018-2019
Title: David Kostyal: Innovator in B-cell Malignancy Treatments
Introduction
David Kostyal is an accomplished inventor based in Akron, OH (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting B-cell malignancies. With a total of 2 patents, his work is paving the way for new therapeutic approaches in treating B-cell lymphomas and leukemias.
Latest Patents
Kostyal's latest patents include innovative antibodies that specifically target the membrane-bound IgM (mIgM) of the B-cell receptor complex. The first patent focuses on the use of these antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias. The second patent details the production of monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b, and mAb3-2b, which were developed through hybridoma cell lines. Both patents highlight the potential of anti-B-cell mIgM antibodies in advancing treatment options for patients suffering from these conditions.
Career Highlights
David Kostyal is currently associated with Welt Bio-molecular Pharmaceutical, LLC, where he continues to innovate in the field of pharmaceuticals. His expertise in antibody development has positioned him as a key player in the fight against B-cell malignancies.
Collaborations
Kostyal collaborates with notable colleagues such as Sydney Welt and Rachel S. Welt, contributing to a dynamic research environment focused on advancing therapeutic solutions.
Conclusion
David Kostyal's work in developing targeted antibodies represents a significant advancement in the treatment of B-cell malignancies. His innovative patents and collaborations are set to make a lasting impact in the field of biotechnology.